- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02284269
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Meta-analysis in Post-Marketing Surveillances for Long-Term Drug Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to integrate the post-marketing surveillances data (Specified use-results surveys on long-term treatment) of the 6 SGLT2 inhibitors approved or applied in Japan and to evaluate the safety and efficacy of long-term use of each under actual clinical practice conditions.
In each post-marketing surveillance, 3000 patients who complete a 3 years treatment are enrolled. A total of 18000 patients are assessed in the meta-analysis.
Study Overview
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Study Plan
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events
Time Frame: up to 3 years
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of cardiovascular events
Time Frame: up to 3 years
|
up to 3 years
|
Incidence of cancer
Time Frame: up to 3 years
|
up to 3 years
|
The change from baseline in vital signs and laboratory data
Time Frame: Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration
|
Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration
|
Incidence of other adverse events
Time Frame: up to 3 years
|
up to 3 years
|
Incidence of drug-related adverse events
Time Frame: up to 3 years
|
up to 3 years
|
Incidence of serious adverse events
Time Frame: up to 3 years
|
up to 3 years
|
The change from baseline in HbA1c
Time Frame: Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration
|
Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration
|
The change from baseline in Fasting Plasma Glucose
Time Frame: Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration
|
Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMDA-A2602
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on SGLT2 Inhibitors
-
Samsung Medical CenterNot yet recruitingHeart Failure, Preserved Ejection FractionKorea, Republic of
-
Sadat City UniversityBeni-Suef UniversityCompleted
-
LMC Diabetes & Endocrinology Ltd.Merck Sharp & Dohme LLC; Syreon CorporationWithdrawnType2 Diabetes
-
University of Texas Southwestern Medical CenterRecruitingDiabetes | Kidney Disease, ChronicUnited States
-
Hamad Medical CorporationRecruiting
-
University of MinnesotaNot yet recruitingAcute Kidney Injury
-
Jeil Pharmaceutical Co., Ltd.CompletedHealthy AdultKorea, Republic of
-
Ewha Womans University Mokdong HospitalEnrolling by invitationDiabetes Mellitus, Type 2 | Atrial Fibrillation | SGLT-2 InhibitorKorea, Republic of
-
Dongying ZhangRecruitingMyocardial Infarction | Diabetes MellitusChina
-
University of PalermoAzienda Ospedaliera Ospedali Riuniti Villa Sofia CervelloRecruitingCirrhosis, Liver | Ascites Hepatic | Diabete Type 2Italy